v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
 12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Cash flows from operating activities    
Net loss from operations $ (23,658,438) $ (16,930,289)
Adjustments to reconcile net loss from continuing operations to net cash (used in) provided by operating activities:    
Depreciation and amortization 3,678,786 3,481,748
Non-cash loss on the sale of Infusionz and select assets, net 0 2,212,542
Gain on the sale of VitaMedica and income from discontinued operations (1,948,538) 0
Loss on the sale of New England Technology 1,737,326 0
Amortization of loan costs 115,787 62,408
Amortization of consideration discount 1,112,676 969,098
Impairment of goodwill and intangible assets 7,869,425 3,746,301
Inventory write-offs 1,812,319 118,990
Loss on impairment of building 336,434 0
Loss on sale of assets related to relocation of facility 569,195  
Gain on sale of interactive offers (237,670) 0
Change in deferred tax asset (344,802) (3,139,227)
Noncontrolling interest 0 (559,967)
Change in derivative 0 1,770
Stock based compensation 1,169,843 3,664,538
Changes in assets and liabilities, net of acquired amounts    
Accounts receivable 675,709 (364,665)
Inventory 2,651,252 (1,366,269)
Prepaid expenses and other assets 106,610 287,797
Operating lease payable 302,050 4,238
Accounts payable and accrued liabilities (944,020) 389,458
Deferred revenue 101,305 0
Net cash used in operating activities - Continuing Operations (4,894,751) (7,421,529)
Net cash provided by operating activities - Discontinued Operations 4,793,374 7,624,206
Net cash (used in) provided by operating activities (101,377) 202,677
Cash flows from investing activities    
Acquisition of Lucky Tail 0 (3,528,239)
Proceeds from the sale of VitaMedica, Inc. 2,100,000 0
Proceeds from the sale of Interactive Offers, net of liabilities paid 203,025 0
Acquisition of Cygnet Online LLC, net (539,348) (1,050,000)
Proceeds from the sale of Infusionz and selected assets 0 5,492,532
Acquisition of property and equipment (932,565) (937,564)
Net cash provided by (used in) investing activities - Continuing Operations 831,112 (23,271)
Net cash (used in) investing activities - Discontinued Operations (4,206,823) (2,551,587)
Net cash used in investing activities (3,375,711) (2,574,858)
Cash flows from financing activities    
Repayment of the senior convertible notes payable 0 (6,305,406)
Proceeds from the issuance of stock 0 6,127,893
Payment on acquisition notes payable (246,761) (751,152)
Proceeds from related party advance 100,000 0
Proceeds from convertible note payable 0 2,650,000
Proceeds on note payable on building 0 3,000,000
Repayment on note payable on building (207,028) (158,434)
Proceeds on note payable, related party 0 1,470,000
Net cash (used in) provided by financing activities - Continuing Operations (353,789) 6,032,901
Net cash used in financing activities - Discontinued Operations 0 (6,318,234)
Net cash used in financing activities (353,789) (285,333)
Net decrease in cash - Continuing Operations (4,417,428) (1,411,899)
Net (decrease) increase in cash - Discontinued Operations 586,551 (1,245,615)
Cash, beginning of period 4,492,292 7,149,806
Cash, end of period 661,415 4,492,292
Supplemental Cash Flow Disclosures    
Interest paid 839,000 2,278,292
Income tax paid 0 0
Non-cash Investing and Financing Activities    
Non-cash proceeds in the sale of VitaMedica 1,900,000 0
Issuance of common stock for acquisition of Cygnet 162,727 0
Issuance of debt for acquisition of Cygnet 300,000 0
Bloomios non-cash payment of receivables, net 845,443 0
Issuance of stock for services 0 140,700
Issuance of stock for interest expense 0 607,004
Issuance of common stock for the repayment of convertible note payable 500,000 0
Liabilities assumed from acquisition of E-Core 0 (7,712,168)
Issuance of stock for acquisition of E-Core 0 6,000,000
Assets available for sale $ 0 $ 1,026,043